Introduction
Anemia of chronic disease (ACD, or anemia of inflammation) is the most prevalent anemia in hospitalized patients (1-3) and develops in subjects with diseases involving acute or chronic immune activation such as infections, malignancies or autoimmune disorders (1). At least three major immunity driven mechanisms contribute to ACD among which the retention of iron within the mononuclear phagocytic system with subsequent development of hypoferremia along with a limited availability of iron for erythroid progenitor cells are of pivotal importance (1, 4). This diversion of iron traffic is induced via regulatory effects of cytokines on iron uptake and release by macrophages (5, 6) and by the activity of the iron and cytokine inducible liver derived peptide hepcidin (7) . Hepcidin affects cellular iron homeostasis after binding to the only known iron export protein ferroportin, resulting in its degradation and blockage of iron transfer from monocytes/macrophages to the circulation (8) (9) (10) . This effect is further aggravated in inflammatory macrophages/monocytes by the autocrine formation of hepcidin (11, 12) .
The role of hepcidin in the pathogenesis of human ACD is supported by the finding that hepcidin levels (i) are significantly increased in patients with ACD (7, 13) and in subjects injected with LPS (14) , (ii) are correlated to iron retention in monocytes/macrophages in vivo (15) and (iii) by the observation that administration of anti-hepcidin antibodies ameliorates the therapy of anemia in mice suffering from brucellosis (16) .
However, a significant number of patients with ACD suffer from concomitant true iron deficiency anemia (IDA) as a consequence of chronic blood loss (ACD/IDA) (1, 17,
18)
The differentiation between ACD and ACD/IDA is of clinical importance because ACD and ACD/IDA patients may need contrasting therapies in terms of iron 6 substitution (1). When investigating patients suffering from ACD and ACD/IDA, we found that ACD/IDA patients had significantly lower serum hepcidin levels than subjects with ACD, although the degree of inflammation was comparable (13) . This observation was confirmed in a rat model of ACD and ACD/IDA (13) and in a mouse model of critical illness associated anemia (19) The activation of BMP signaling through the SMAD1/5/8 pathway is negatively affected by the inhibitory SMADs, SMAD6 and SMAD7, and proteins such as TOB1 and TOB2 (34).
In addition to iron and inflammation, the expression of hepcidin is controlled by hypoxia, endoplasmatic reticulum stress, erythropoietic activity and erythropoiesis driven signals (25, (35) (36) (37) (38) (39) (40) . Interestingly, STAT3 mediated transcriptional hepcidin activation is decreased in LPS treated mice exposed to erythropoietin (41) pointing to a hierarchy of different signals for hepcidin induction.
However, so far no data were available on the regulatory networks controlling hepcidin expression in inflammatory anemia and how they are affected by concomitant iron deficiency in vivo. In a first set of experiments rats were inoculated on day 0 with an i.p. injection of PG-APS (group A streptococcal peptidoglycan-polysaccharide) (Lee Laboratories, Grayson, GA) suspended in 0.85% saline with a total dose of 15 µg rhamnose/g body weight which has been shown to induce chronic arthritis and anemia in rats (13) .
Design and Methods

Animals
Carrier-immunized control rats received i.p. injections of sterile 0.85% saline.
One group of PG-APS treated and one group of carrier-immunized rats was phlebotomized, starting one week before sacrifice. 1.8 mL of blood were taken daily for five consecutive days. Each group consisted of six rats. Three weeks after PG-8 APS administration, rats were euthanized and tissue was harvested for RNA and protein extraction.
In Lewis rats total body iron is 4-5 mg/100 g body weight. We used rats with 200-250 mg body weight. During the experiment 9 mL of whole blood were taken. This corresponds to a loss of 4.5 mg iron. Thus phlebotomized rats lose approximately 30-50% of total body iron during the phlebotomy period.
In a second set of experiments one group of PG-APS treated rats was put on an iron deficient diet (5.2 mg Fe/kg; C1038 from Altromin) one week before PG-APS administration and kept on the iron deficiency diet during the entire observation period. Each group consisted of six rats. Again, three weeks after PG-APS administration, rats were euthanized and tissue was harvested for RNA-and protein extraction. Western Blotting: Cytosolic protein extracts were prepared from nitrogen frozen tissue as previously described (12) . Nuclear extracts were prepared from freshly isolated tissue using a commercial available Kit (NE-PER, Thermo scientific, Rockford, USA). Membrane protein extracts were prepared from nitrogen frozen tissue as previously described (42). Western blotting of cellular extracts was done as described (12) . STAT3-antibody (final concentration 0.1 µg/mL), phospho-STAT3 (Ser727)-antibody (0.1 µg/mL), phospho-SMAD1/SMAD5/SMAD8-antibody (0.1 µg/mL), SMAD5-antibody (0.1 µg/mL), SMAD4-antibody (0.1 µg/mL, all five from Cell Signaling Technology, Inc., Danvers, USA), SMAD6-antibody (0.5 µg/mL), SMAD7-antibody (0.5 µg/mL, both from Acris Antibodies, Herford, Germany), hemojuvelin-antibody (1:100) (43), TOB1-antibody (0.5 µg/mL) and TOB2-antibody (0.5 µg/mL, all two from Santa Cruz Biotechnology, Heidelberg, Germany), rat/HRP-antibody (0.1µg/mL, Dako, Glostrup, Denmark) or ß-actin-antibody (2 µg/mL, Sigma, Munich, Germany) were used as described (13) .
Protein levels were quantified by densitometry using Quantity One Basic software (Bio-Rad, CA). The supplementary figures Fig.1 and .2 show the detailed blots used for densitometric quantification.
All antibodies are, according to manufactures' information, specific for the respective rat antigen. As an additional control we also performed blocking experiments with the antibodies used in our study to ensure their specificity.
Immunohistochemistry: Analyses were performed as described (44). In brief, formalin fixed sections of paraffin-embedded tissues were mounted on glass slides. 
Data analysis
All parameters were tested for normality by Kolmogorov-Smirnov test. Calculations for statistical differences between the various groups were carried out by ANOVA with Bonferroni correction for multiple tests. Spearman-rho test was used for correlation analyses. A value of p < 0.05 was considered statistically significant. All statistical analyses were carried out using the Statistical Package for the Social Sciences (SPSS) software package version 15.0 (SPSS Inc., Chicago, IL, USA).
Results
Based on our previous observation of increased hepcidin expression in humans and rats suffering from ACD, and of reduced hepcidin levels in ACD individuals with concomitant true iron deficiency (ACD/IDA) (13) we herein tried to elucidate the pathways underlying contrasting hepcidin expression under these circumstances. For this aim, we used rats injected with PG-APS which resulted in the development of a chronic arthritis associated with a chronic persisting inflammatory anemia, bearing the typical features of ACD (13) . Additional iron deficiency was induced by phlebotomy (ACD/IDA) as detailed in materials and methods. To study differences in hepcidin upstream signaling pathways between ACD and ACD/IDA animals, we first investigated the inflammation inducible STAT3 pathway in rat liver (Fig.1A, C) . We found that STAT3 phosphorylation (pSTAT3) was significantly increased in the livers of ACD (p<0.001) and ACD/IDA (p<0.001) rats when compared to control and IDA rats. In contrast, we observed no significant difference in STAT3 activation between ACD and ACD/IDA animals ( Fig.1A, C) .
Consecutively, we analyzed the signaling activity via the SMAD1/5/8 pathway (Fig.1B, D) . We found that SMAD1/5/8 phosphorylation (pSMAD1/5/8) was lower in IDA than in control animals. In contrast, we observed significantly increased SMAD1/5/8 phosphorylation in rats suffering from ACD when compared to control rats (p=0.001) and ACD/IDA rats (p<0.001) (Fig 1B, D) . To further investigate the mechanisms causing differences in hepatic SMAD1/5/8 phosphorylation between ACD and ACD/IDA rats, we analyzed known pathways affecting SMAD1/5/8 phosphorylation and its nuclear trafficking.
While BMP2, 4 and 9 mRNA levels were not significantly different between the various groups (data not shown), BMP6 mRNA concentrations were significantly lower in IDA (p<0.05) and ACD/IDA (p<0.001) rats as compared to control and ACD animals ( Fig.2A) . BMP7 mRNA levels were found to be significantly decreased in association with inflammation, ACD (p<0.001) and ACD/IDA (p<0.001) rats, when compared with control rats, but no difference was observed between ACD and ACD/IDA (Fig.2B ).
Because the co-SMAD SMAD4 forms a complex with pSMAD1/5/8 before translocating to the nucleus, we determined SMAD4 levels in the different anemia groups. SMAD4 protein expression was induced in ACD (p<0.001) and ACD/IDA (p=0.001) as compared to controls, while no differences were observed between ACD and ACD/IDA (Fig.3A, F) .
Next, we analyzed the expression of SMAD6 and SMAD7, two inhibitory proteins in the BMP/SMAD signal transduction pathway. While no statistically significant differences in SMAD6 expression were found between the different groups (Fig.3B, F) , SMAD7 protein expression was significantly lower in ACD than in control rats (p<0.05). In contrast, ACD/IDA animals presented with significantly higher SMAD7 levels than ACD rats (p<0.05) (Fig.3C, F) .
The expression of TOB1 and TOB2, two additional negative regulators of the BMP signaling pathway, was lower in ACD and ACD/IDA when compared with control or IDA rats, respectively. However, no significant differences were evident when comparing ACD with ACD/IDA animals ( Fig.3D , E, F) pointing to a modulation of TOB1 and TOB2 expression by inflammation.
So far, we found that BMP6 mRNA expression and SMAD7 protein levels were significant different between ACD and ACD/IDA rats, and that these parameters were significantly correlated to Hamp mRNA levels in the liver (r=-0.738 p=0.037 for SMAD7; r=0.857 p=0.014 for BMP6).
However, using the phlebotomy model to induce ACD/IDA we could not differentiate whether the alterations in BMP6 and SMAD7 expression are caused by changes of liver iron concentrations or erythropoietic activity, although hemoglobin levels were not different between ACD and ACD/IDA animals (13). As a surrogate for erythropoietic activity we determined serum erythropoietin levels which were of interest because erythropoietin has previously been demonstrated to inhibit hepcidin formation (10, 37, 40). As shown in Table 2 SMAD7 levels correlate positively (r=0.818 p=0.002) and BMP6 expression inversely with serum EPO levels (r=-0.731 p=0.016), while the opposite was true for the correlations between liver iron concentrations with BMP6 (r=0.782 p=0.008) or SMAD7 (r=-0.636 p=0.035) expression, mirroring the differences in serum iron concentrations (13) . As we could not estimate to which extend changes in SMAD7 and BMP6 expression can be referred to either modifications of erythropoietic activity or changes in hepatic iron availability we next compared rats with inflammatory anemia and two different forms of concomitant iron deficiency, i.e. ACD rats undergoing phlebotomies versus ACD rats with dietary iron restriction.
When inflammatory anemia was induced in animals kept on an iron deficient diet, the relative changes in Hamp mRNA expression and the corresponding alterations of SMAD1/5/8 activity observed three weeks after PG-APS injection were exactly the same as in the ACD group undergoing phlebotomy (Fig.4 A, B, H) . BMP6 mRNA and protein levels were reduced in both groups of true iron deficient ACD animals as compared to ACD rats ( Fig.4C and Fig.4I a-c) . In contrast, SMAD7 protein levels were differently affected upon phlebotomy or iron deficient diet. While regular phlebotomy significantly increased SMAD7 protein levels (p<0.05), dietary iron restriction decreased SMAD7 expression in ACD rats (p<0.001) (Fig.4D, H) .
Interestingly, we found SMAD7 mRNA levels to be significantly decreased in rats treated with phlebotomy (P<0.05) and on iron restricted diet (p<0.001) (Fig.4E ). This indicates that the reported differences in SMAD7 protein levels as a function of alternative iron replacing strategies, phlebotomy versus dietary iron restriction, respectively, are likely due to a post-transcriptional regulation of SMAD7 in an iron independent manner as liver iron levels did not differ between the two iron deficient groups (data not shown). However, we found significantly elevated serum EPO levels in the phlebotomized group compared to the group receiving an iron deficient diet (p<0.001; Supplemental Tab.1).
As TMPRSS6 protein expression has been reported to be rapidly induced by oral iron deprivation (45), we analyzed TMPRSS6 in ACD rats with true iron deficiency due to phlebotomy or iron deficient diet. In accordance with previous data (45), we found no changes in hepatic TMPRSS6 mRNA expression between the different anemia groups (data not shown). Unfortunately, no commercial available TMPRSS6 antibody works with rat samples, thus we were not able to analyze TMPRSS6 protein expression. However, as a surrogate for TMPRSS6 activity we investigated mHJV expression using liver membrane fractions. While in phlebotomized rats only a trend toward lower hepatic mHJV expression was found (Fig.4F, H and 4Id-e) , a significantly reduced mHJV expression was observed in ACD rats on an iron deficient diet (Fig.4F, H and 4Id-e) as compared to ACD rats. In contrast, neither phlebotomy nor iron deficient diet significantly changed HJV mRNA expression (Fig.4G ).
Discussion
We and others reported increased hepcidin expression in patients suffering from ACD and in mammalian models mimicking ACD (7, 13, 14, 19) .
In contrast, serum hepcidin levels and/or liver Hamp mRNA expression were significantly lower in patients and mammals suffering from ACD with true iron deficiency (ACD/IDA) when compared with ACD alone (13, 19) , indicating different signaling pathways and hierarchies between inflammatory anemia (ACD) and inflammatory anemia with associated true iron deficiency (ACD/IDA).
In accordance with a previous observation made in LPS challenged mice (41), we observed increased STAT3 phosphorylation in ACD rats which was not altered Therefore, we analyzed the effects of two forms of true iron deficiency on Hamp transcription and SMAD signaling in ACD rats which underwent either phlebotomy or were exposed to dietary iron restriction. BMP6 mRNA levels were not different between both truly iron deficient ACD groups. As both groups did not differ in liver iron concentrations but did so in serum EPO levels BMP6 expression appears to be rather affected by tissue iron levels which goes along with the observation of iron mediated induction of BMP6 (47, 49, 50) . SMAD7 expression, in contrast, was differentially regulated between the two groups. While this could not be traced back to differences in liver iron content, phlebotomized rats showed significantly higher EPO levels as an indicator of stimulated erythropoiesis when compared to ACD rats on an iron deficient diet.
These data suggest that SMAD7 expression is influenced by both, changes in iron status and erythropoiesis activity, however, in opposite directions (43).
Although, the expression of the inhibitory SMAD7 is decreased in rats on an iron deficient diet, SMAD1/5/8 phosphorylation is low and comparable to phlebotomized rats. Thus, we explored alternative pathways for SMAD transactivation, and we found less mHJV in liver cell membranes of low-iron fed ACD rats than in ACD rats on a normal diet which is in agreement with data indicating increased TMPRSS6 activity in association with dietary iron restriction (45, 50). In the cause of iron deficiency. This is on the one hand due to reduced expression of BMP6 as a consequence of low iron availability. On the other hand, phlebotomy but not dietary iron deficiency induces SMAD7 protein expression, an inhibitor of the SMAD1/5/8 transactivating pathway. This appears therefore not to be the consequence of low iron availability, because SMAD7 levels were reduced in ACD rats receiving an iron poor diet, but rather being due to the induction of erythropoietic activity following phlebotomy as evidenced by increased circulating erythropoietin levels or hypoxia as a consequence of blood loss. As iron deficiency induced by phlebotomy as well as by low iron diet inhibits SMAD7 transcription the differences in SMAD7 protein expression were unexpected. However, SMAD7 has been reported to be regulated post-transcriptionally (53) and post-translationally (54) . The coactivator p300 acetylates and stabilizes SMAD7, thus preventing its ubiquitination and degradation in the proteasome (53) . P300 interacts with central mediators of erythropoiesis (55) Calculations for statistical differences between the various groups were carried out by ANOVA technique and Bonferroni correction for multiple tests. Liver tissue samples were subjected to immunoblot analysis using antibodies against SMAD4 (A), SMAD6 (B), SMAD7 (C), TOB1 (D) and TOB2 (E).
Protein levels were quantified by densitometry. Expression levels were normalized to the housekeeping gene ß-actin.
Data are depicted as lower quartile, median and upper quartile (boxes) and minimum/maximum ranges (whiskers). Statistic outliers are displayed as circles.
Calculations for statistical differences between the various groups were carried out by 27 ANOVA technique and Bonferroni correction for multiple tests. Representative blots for each protein are shown in F.
For blots used for quantification by densitometry please see Suppl. Fig.1 . The blots used for quantification by densitometry are shown in Suppl. Fig.2 .
Liver cytoplasmatic extracts were subjected to immunoblot analysis using antibodies against SMAD7 (D,F) and mHJV (E,F). Protein levels were quantified by
